Yabao Pharmaceutical Group Co., Ltd

Equities

600351

CNE000001CM5

Pharmaceuticals

End-of-day quote Shanghai S.E. 06:00:00 2024-04-28 pm EDT 5-day change 1st Jan Change
6.48 CNY +0.78% Intraday chart for Yabao Pharmaceutical Group Co., Ltd +5.88% -6.09%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Yabao Pharma Gets Nod to Register Asthma Drug Montelukast Sodium Granules MT
Tranche Update on Yabao Pharmaceutical Group Co., Ltd's Equity Buyback Plan announced on May 9, 2023. CI
Yabao Pharmaceutical Group Co., Ltd announces an Increase in Equity Buyback. CI
Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Tranche Update on Yabao Pharmaceutical Group Co., Ltd's Equity Buyback Plan announced on May 9, 2023. CI
Yabao Pharmaceutical Group Co., Ltd(XSSC:600351) added to S&P Global BMI Index CI
Hunan Caprico Biotechnologies Co., Ltd. announced that it has received funding from Guangzhou Huangpu Biomedical Fund Management Co., Ltd., Yabao Pharmaceutical Group Co., Ltd CI
Yabao Pharmaceutical Takes Over Rights of Traditional Chinese Medicine for 26 Million Yuan MT
Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Tranche Update on Yabao Pharmaceutical Group Co., Ltd's Equity Buyback Plan announced on May 9, 2023. CI
Yabao Pharmaceutical Group Co., Ltd commences an Equity Buyback Plan for CNY 300 million worth of its shares, under the authorization approved on April 24, 2023. CI
Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Yabao Pharmaceutical Unit Submits FDA Application for Osteoarthritis Drug MT
Yabao Pharmaceutical Unit's Sorafenib Tablets Enters US Markets MT
Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Fineimmu announced that it has received CNY 100 million in funding from Yabao Pharmaceutical Group Co., Ltd, Panacea Venture Management Co., Ltd. and another investor CI
Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Indian Indices End Lower; Bajaj Finance Slides 7% MT
Lupin to Market Pediatric Medicines in China Under New Deal with Yabao Pharmaceutical MT
Lupin Limited and Yabao Pharmaceutical Co. Inc. Announce Strategic Partnership in China CI
Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Chart Yabao Pharmaceutical Group Co., Ltd
More charts
YABAO PHARMACEUTICAL GROUP CO. LTD is a China-based company, principally engaged in the research and development, production and distribution of pharmaceuticals. The Company mainly provides light pastes, tablets, injections, capsules, oral liquids, bulk drugs and other pharmaceutical products. The Company is also engaged in the wholesaling and trading of pharmaceuticals. The Company distributes its products within domestic market and to overseas markets.
Calendar
More about the company
  1. Stock Market
  2. Equities
  3. 600351 Stock
  4. News Yabao Pharmaceutical Group Co., Ltd
  5. Yabao Pharma Gets Nod to Register Asthma Drug Montelukast Sodium Granules